Microwave-assisted heating: innovative use in hydrolytic forced degradation of selected drugs
Source abstract
Abstract
Stress testing has been executed to illuminate the inherent stability characteristics of drug substances and drug products. As an alternative to the conventional hydrolytic forced degradation, which is carried out at the elevated temperature for an elongated time period, microwave-assisted heating is believed to be more promising. The later technique offers many advantages over conventional heating technique like fast, efficient heat source, a more reproducible result due to the control of parameters, eco-friendly, unlike conventional heating source, it heats up only the molecules which absorb microwave energy and not the apparatus first. Present work reports microwave-assisted hydrolytic degradation studies of selected drugs, namely Lurasidone, Risperidone, Paliperidone, Alprazolam, Escitalopram, Atomoxetine, Repaglinide, Furosemide, Hydrochlorothiazide and Olmesartan. The degradation samples were analysed by using high-performance liquid chromatography techniques. The degradation products generated by conventional and microwave heating methods were compared with respect to relative retention time. Though selected drugs have different chemical structures, the unaltered degradation profile was observed when conventional heating was replaced by microwave heating. With the proposed microwave heating technique, degradation products were generated in drastically lesser time from many hours to minutes without generation of secondary degradation products.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Microwave-Assisted Synthesis and Applications · Multicomponent Synthesis of Heterocycles · Chemical Synthesis and Reactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Pharmacy, Nirma University, Ahmedabad, India
References (62)
Show source-provided references
1. Amasa SR · Scholars Res Library · 2014 · 6 · 312
2. 10.5402/2012/58237510.5402/2012/582375 ↗
3. 10.1007/s10337-013-2537-010.1007/s10337-013-2537-0 ↗
4. 10.1365/s10337-007-0415-310.1365/s10337-007-0415-3 ↗
5. Bhagwate S · J Appl Pharm Sci · 2013 · 3 · 88
6. Bhattacharyya I · Int J Adv Pharm Anal · 2015 · 5 · 36
7. 10.1155/2014/52318410.1155/2014/523184 ↗
8. 10.1080/10826076.2011.60150310.1080/10826076.2011.601503 ↗
9. 10.1093/chromsci/bms01110.1093/chromsci/bms011 ↗
10. 10.1016/0378-5173(88)90178-010.1016/0378-5173(88)90178-0 ↗
11. 10.1016/0040-4020(95)00662-R10.1016/0040-4020(95)00662-R ↗
12. Chauhan PP · Eurasian J Anal Chem · 2016 · 11 · 103
13. Chhabda PJ · Int J Pharm Res Dev · 2013 · 5 · 103
14. Da Silva FEB · Rev Bras Farm · 2013 · 94 · 265
15. 10.1093/chromsci/bmt17610.1093/chromsci/bmt176 ↗
16. 10.1155/2011/12491710.1155/2011/124917 ↗
17. Dhaneshwar SR · J AOAC Int · 2008 · 92 · 13810.1093/jaoac/92.1.138 ↗
18. 10.1016/j.jpba.2004.07.01410.1016/j.jpba.2004.07.014 ↗
19. 10.1002/jps.260067062110.1002/jps.2600670621 ↗
20. Gonsalves AR · Online J Org Chem · 2010 · 5 · 128
21. Hamrapurkar PD · Int J Appl Sci Eng · 2013 · 11 · 13710.5937/jaes11-4122 ↗
22. Hanyšová L · Chem Papers · 2005 · 59 · 99
23. 10.1080/0148391870806675010.1080/01483918708066750 ↗
24. 10.1016/j.jpba.2006.12.00310.1016/j.jpba.2006.12.003 ↗
25. International Conference of Harmonization · Stability testing of new drug substances and products · 2003
26. Jadhav SA · Chromatogr Res Int · 2011 · 2011 · 1
27. Jain P · Chem Ind Chem Eng Quart/CICEQ · 2012 · 18 · 59510.2298/CICEQ111204035J ↗
28. 10.1556/AChrom.24.2012.3.610.1556/AChrom.24.2012.3.6 ↗
29. 10.1093/chromsci/bms17710.1093/chromsci/bms177 ↗
30. 10.1016/j.jpba.2014.03.03510.1016/j.jpba.2014.03.035 ↗
31. 10.1016/S0040-4020(01)00906-110.1016/S0040-4020(01)00906-1 ↗
32. 10.1365/s10337-008-0735-y10.1365/s10337-008-0735-y ↗
33. Mahajan AA · J Braz Chem Soc. · 2012 · 23 · 445
34. 10.4103/0975-7406.8444110.4103/0975-7406.84441 ↗
35. 10.3797/scipharm.1006-1010.3797/scipharm.1006-10 ↗
36. Patel SK · J AOAC Int · 2010 · 93 · 120710.1093/jaoac/93.4.1207 ↗
37. Pathak A · J AOAC Int · 2008 · 91 · 134410.1093/jaoac/91.6.1344 ↗
38. 10.1093/chromsci/48.7.60110.1093/chromsci/48.7.601 ↗
39. Prajapati DK · World J Pharm Pharmaceut Sci · 2015 · 4 · 1714
40. 10.1016/j.jpba.2011.07.04210.1016/j.jpba.2011.07.042 ↗
41. 10.1093/chromsci/bms06210.1093/chromsci/bms062 ↗
42. 10.1016/j.jpba.2010.06.01910.1016/j.jpba.2010.06.019 ↗
43. 10.1093/chromsci/48.7.59510.1093/chromsci/48.7.595 ↗
44. 10.4236/ajac.2012.3202210.4236/ajac.2012.32022 ↗
45. 10.1016/S0731-7085(03)00216-410.1016/S0731-7085(03)00216-4 ↗
46. Sawant SD · J Pharm Res · 2013 · 6 · 39
47. 10.1016/j.ijpharm.2015.02.07110.1016/j.ijpharm.2015.02.071 ↗
48. 10.1016/j.arabjc.2013.04.01210.1016/j.arabjc.2013.04.012 ↗
49. Sharma D · Acta Pharm Sci · 2010 · 52 · 345
50. Sharma MC · Int J ChemTech Res · 2011 · 3 · 210
51. 10.4172/2153-2435.100027810.4172/2153-2435.1000278 ↗
52. 10.3797/scipharm.1011-0610.3797/scipharm.1011-06 ↗
53. Sonawane S · J Liq Chromatogr Relat Technol · 2013 · 36 · 215610.1080/10826076.2012.717054 ↗
54. 10.18579/jpcrkc/2015/14/1/7837010.18579/jpcrkc/2015/14/1/78370 ↗
55. Suthar A · Int J PharmTech Res · 2009 · 1 · 568
56. 10.1093/chrsci/49.10.78010.1093/chrsci/49.10.780 ↗
57. 10.1016/j.jpba.2014.11.03510.1016/j.jpba.2014.11.035 ↗
58. 10.1016/j.jpba.2004.05.02210.1016/j.jpba.2004.05.022 ↗
59. 10.1080/1082607090290160610.1080/10826070902901606 ↗
60. Trivedi RK · J Appl Pharm Sci · 2013 · 3 · 87
61. 10.1016/j.jpba.2015.01.05910.1016/j.jpba.2015.01.059 ↗
62. 10.1016/S1359-6446(02)02178-510.1016/S1359-6446(02)02178-5 ↗